Achyut Healthcare reported a significant expansion in top-line growth for FY26, with revenue from operations rising 281% year-on-year to ₹1,159.5 lakh. However, the bottom line contracted as net profit after tax fell 39% to ₹31.6 lakh, compared to ₹51.5 lakh in the previous fiscal year.

The Ahmedabad-based pharmaceutical firm submitted its 31st Annual Report on September 5, 2026, disclosing audited financials for the year ended March 31, 2026. Alongside the results, the Board of Directors approved a Scheme of Amalgamation with Zenith Healthcare Limited, subject to shareholder and regulatory approvals.

Financial Performance

The company’s total income for FY26 stood at ₹1,197.2 lakh, driven primarily by the surge in operational revenue. While revenue grew sharply, other income declined significantly from ₹92.1 lakh in FY25 to ₹37.7 lakh in FY26. This drop in non-operating income contributed to the overall compression in profitability despite higher sales volumes.

Expenses rose proportionally with revenue. Purchase of traded goods increased to ₹1,018.9 lakh from ₹300.1 lakh in FY25. Other expenses also saw a substantial jump to ₹126.1 lakh, up from ₹18.9 lakh, reflecting increased operational activity and bad debts written off amounting to ₹15.0 lakh.

What the Numbers Show

A key divergence in the financial data is the decoupling of revenue growth from profit generation. While revenue more than tripled, net profit nearly halved. This indicates that the cost structure scaled faster than sales, with gross margins likely under pressure. Furthermore, the sharp decline in other income—down 59% YoY—suggests that the previous year’s profits were partially buoyed by non-recurring or interest-based gains that did not materialize at similar levels in FY26.

Corporate Developments

The Board recommended no dividend for FY26, opting to retain profits for business growth. The company has been actively expanding its manufacturing capabilities, with capital work in progress rising to ₹2,788.5 lakh from ₹1,829.0 lakh in FY25. Commercial production from its new facilities is expected to commence in January 2026.

Additionally, Achyut Healthcare migrated its listing from the BSE SME platform to the Main Board effective January 2, 2026. The Board also approved the re-appointment of Managing Director Jigen J. Modi and two independent directors, Sonu Lalitkumar Jain and Rutvik Sanjaykumar Thakkar, for five-year terms starting November 1, 2026.

Achyut Healthcare Limited has scheduled its 31st Annual General Meeting (AGM) for September 29, 2026. The meeting will address the reappointment of Managing Director Jigen J. Modi and two independent directors for five-year tenures.

The board of directors approved these appointments during its meeting on September 5, 2026. The reappointments require shareholder approval via special resolution under Section 196 of the Companies Act, 2013 and SEBI LODR regulations.

Key Board Decisions

The board approved the following appointments effective November 1, 2026, through October 31, 2031:

• Jigen J. Modi: Reappointed as Managing Director with a remuneration of up to ₹50,000 per month.
• Sonu Lalitkumar Jain: Reappointed as Non-Executive Independent Director with sitting fees up to ₹50,000.
• Rutvik Sanjaykumar Thakkar: Reappointed as Non-Executive Independent Director with sitting fees up to ₹50,000.

Additionally, the board considered the reappointment of Mahendra C. Raycha as a director retiring by rotation. This requires approval via an ordinary resolution.

AGM Details

The 31st AGM will be held on September 29, 2026, at 10:30 am through video conferencing or other audio-visual means (VC/OAVM). The record date for determining voting eligibility is September 22, 2026.

M/s. Kamlesh M Shah & CO., PCS has been appointed as the scrutinizer for the e-voting process. Remote e-voting will be available from September 26, 2026, to September 28, 2026, facilitated by National Securities Depository Limited (NSDL).

Director Profiles

All three directors attended eight board meetings in the preceding period. None hold equity shares in the company, except for unrelated holdings in other entities such as Zenith Healthcare Limited and JFL Lifescience Limited.